Results 1 to 10 of about 17,354 (253)

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy. [PDF]

Future Oncol
We describe in this review the historical evidence leading up to the concept and design of Vigil and subsequent clinical applications including safety and efficacy in a randomized, controlled Phase IIB trial.
Nemunaitis J, Stanbery L, Walter A, Wallraven G, Nemunaitis A, Horvath S, Bognar E, Rao D, Engle S, Brun S, Ghisoli M, Rocconi RP, Monk BJ, Coleman RL.   +13 more
europepmc   +4 more sources

Vigil

Apparatus. Film, Media and Digital Cultures of Central and Eastern Europe, 2020
Tibor Hajas's video and article.
Tibor Hajas
doaj   +3 more sources

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product [PDF]

Scientific Reports
Retrospective data support overall survival (OS) advantage to high clonal tumor mutation burden (cTMB), high clonal neoantigen load (cNEO) and low intratumor heterogeneity (ITH) in cancer patients who receive immunotherapy.
David Willoughby, Ernest Bognar, Laura Stanbery, Casey Nagel, Gladice Wallraven, Aman Pruthi, Nicholas Bild, Ericca Stamper, Donald Rao, Adam Walter, John Nemunaitis   +10 more
doaj   +3 more sources

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer

Clinical Medicine Insights: Oncology, 2022
Background: Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy which expresses granulocyte-macrophage colony-stimulating factor and decreases expression of furin and downstream TGF-β1 and TGF-β2.
Minal Barve, Phylicia Aaron, Luisa Manning, Ernest Bognar, Gladice Wallraven, Staci Horvath, Laura Stanbery, John Nemunaitis   +7 more
doaj   +2 more sources

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6

Vaccines, 2021
Colorectal cancer is the third most diagnosed cancer in the United States. Five-year survival rates remain low and many patients will develop liver metastasis.
Vedin Barve, Ned Adams, Laura Stanbery, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Minal Barve, John Nemunaitis   +8 more
doaj   +2 more sources

Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials

Frontiers in Oncology, 2022
In recent years, many clinical trials have shown the safety and efficacy of Gemogenovatucel-T (Vigil) in the treatment of advanced OC patients. The purpose of this study was to explore the safety and efficacy of Gemogenovatucel-T (Vigil) in the first ...
Yixin Zhang, Yixin Zhang, Li Zhang, Yuli Zhao, Yuli Zhao, Sen Wang, Sen Wang, Li Feng   +7 more
doaj   +2 more sources

The Vigil Magnetometer for Operational Space Weather Services From the Sun‐Earth L5 Point

Space Weather
Severe space weather has the potential to cause significant socio‐economic impact and it is widely accepted that mitigating this risk requires more comprehensive observations of the Sun and heliosphere, enabling more accurate forecasting of significant ...
J. P. Eastwood, P. Brown, W. Magnes, C. M. Carr, M. Agu, R. Baughen, G. Berghofer, J. Hodgkins, I. Jernej, C. Möstl, T. Oddy, A. Strickland, A. Vitkova   +12 more
doaj   +2 more sources

Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers [PDF]

Annals of Clinical and Translational Neurology
Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose ...
Andreas Meier, Spyros Papapetropoulos, Andrew Marsh, Kelly Neelon, David Stiles, Ryan O'Mara, Evan A. Thackaberry, Marco Colonna, Raj Rajagovindan   +8 more
doaj   +2 more sources

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

Vaccines, 2021
Aim: To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil. Patients and Methods: Recurrent ovarian cancer patients (n = 21) enrolled in prior clinical trials.
Rodney P. Rocconi, Laura Stanbery, Luciana Madeira da Silva, Robert A. Barrington, Phylicia Aaron, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Adam Walter, John Nemunaitis   +10 more
doaj   +2 more sources

3D engineered scaffold for large-scale Vigil immunotherapy production [PDF]

Scientific Reports
Previously, we reported successful cellular expansion of a murine colorectal carcinoma cell line (CT-26) using a three-dimensional (3D) engineered extracellular matrix (EECM) fibrillar scaffold structure.
Fabienne Kerneis, Ernest Bognar, Laura Stanbery, Seongjun Moon, Do Hoon Kim, Yuxuan Deng, Elliot Hughes, Tae-Hwa Chun, Darron Tharp, Heidi Zupanc, Chris Jay, Adam Walter, John Nemunaitis, Joerg Lahann   +13 more
doaj   +2 more sources